NAFLD somewhat treated in children with 2,000 IU Vitamin D daily – RCT Aug 2021

Vitamin D and nonalcoholic fatty liver disease in children: a randomized controlled clinical trial

Eur J Pediatr. 2021 Aug 30. doi: 10.1007/s00431-021-04243-4   Publisher wants $40 for the PDF
Doaa El Amrousy 1 2, Dina Abdelhai 3 4, Dina Shawky 5 4

What is Known:

• Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in pediatrics.
• Several studies reported a negative association between low serum vitamin D level and grades of NAFLD.

What is New:

• Vitamin D supplementation has significantly decreased hepatic steatosis and lobular inflammation and improved the grades of NAFLD in children, confirmed by liver biopsy, but no effect on hepatocyte ballooning or fibrosis was observed.
• Adjuvant vitamin D supplementation is recommended in children with NAFLD.

Vitamin D is reported to have anti-inflammatory and insulin-sensitizing effects, yet vitamin D effects on hepatic fat content in children with nonalcoholic fatty liver disease (NAFLD) are not studied sufficiently. We aimed to evaluate the role of vitamin D supplementation on the hepatic fat content and NAFLD progression in children. This randomized controlled clinical trial was performed on 109 children with biopsy-proven NAFLD; only 100 patients completed the study.

Patients were randomly assigned into two groups: the treatment group who received 2000 IU/day vitamin D for 6 months and the control group who received a placebo. Anthropometric measurements, vitamin D levels, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total cholesterol (TC), serum triglyceride (TG), low-density lipoprotein (LDL), high-density lipoprotein (HDL), fasting blood glucose (FBG), fasting blood insulin level (FBI), homeostasis model assessment of insulin resistance (HOMA-IR), and serum calcium level were measured at the beginning and the end of the study.

Liver biopsy was taken before and at the end of the study for all included children. There was a significant improvement of the hepatic steatosis and lobular inflammation by liver biopsy in the treatment group after treatment. However, there was no significant effect on the hepatocyte ballooning or hepatic fibrosis. There were significant decrease of AST, ALT, TG, LDL, FBG, FBI, and HOMA-IR and significant increase of vitamin D levels and HDL in the treatment group compared to the placebo group (P < 0.05).

Conclusion: Vitamin D supplementation was found to be beneficial in the treatment of NAFLD in children
.Trial registration: www.pactr.org , PACTR201710002634203.

References

1. Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, Hirschhom JN, O’Donnell CJ, Fox CS (2010) Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 51(6):1979–1987 - DOI
2. Haukeland JW, Damås JK, Konopski Z, Løberg EM, Haaland T, Goverud I, Torjesen PA, Birkeland K, Bjøro K, Aukrust P (2006) Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 44(1167):74
3. Flores M (2005) A role of vitamin D in low intensity chronic inflammation and insulin resistance in type 2 diabetes mellitus? Nutr Res Rev 18(175):82
4. Forouhi NG, Luan JA, Cooper A, Boucher BJ, Wareham NJ (2008) Baseline serum 25–hydroxy vitamin D is predictive of future glycemic status and insulin resistance. Diabetes 57(10):2619–2625 - DOI
5. Rhee EJ, Kim MK, Park SE, Park CY, Baek KH, Lee WY, Kang MI, Park SW, Kim SW, Oh KW (2013) High serum vitamin D levels reduce the risk for nonalcoholic fatty liver disease in healthy men independent of metabolic syndrome. Endocr J 60(6):743–752 - DOI
6. Barchetta I, Angelico F, Ben MD, Baroni MG, Pozzilli P, Morini S, Cavallo MG (2011) Strong association between non-alcoholic fatty liver disease (NAFLD) and low 25 (OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med 9(1):85 - DOI
7. Nakano T, Cheng YF, Lai CY, Hsu LW, Chang YC, Deng JY, Huang YZ, Honda H, Chen KD, Wang CC, Chiu KW, Jawan B, Eng HL, Goto S, Chen CL (2011) Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J Hepatol 55(2):415–425 - DOI
8. Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, Arcaro G (2007) Associations between serum 25-hydroxyvitamin D 3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 17(7):517–524 - DOI
9. Roth CL, Elfers CT, Figlewicz DP, Melhorn SJ, Morton GJ, Hoofnagle A, Yeh MM, Nelson JE, Kowdley KV (2012) Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation. Hepatology 55(4):1103–1111 - DOI
10. Dasarathy J, Periyalwar P, Allampati S, Hawkins CA, Brandl PT, Khiyami A, McCullough AJ, Dasarathy S (2012) Hypovitaminosis D associated with more advanced non-alcoholic fatty liver disease. Hepatology 56(S1):889A-890A
11. Nobili V, Giorgio V, Liccardo D, Bedogni G, Morino G, Alisi A, Cianfarani S (2014) Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. Eur J Endocrinol 170(4):547–553 - DOI
12. Egyptian growth curves: Egyptian growth curve for boys and girls 2–21 years body mass index for age percentile diabetes and endocrine metabolism, Pediatric Unit Cairo University children hospital (2008). http://dempuegypt.blogspot.com.eg/
13. Fernandez GR, Redden DT, Pietrobella A, Allison DB (2004) Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. J Pediatr 145:439–444 - DOI
14. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930 - DOI
15. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(1313):1321
16. Salehpour A, Hosseinpanah F, Shidfar F, Vafa M, Razaghi M, Dehghani S, Hoshiarrad A, Gohari M (2012) A 12-week double-blind randomized clinical trial of vitamin D3 supplementation on body fat mass in healthy overweight and obese women. Nutr J 11(1):78 - DOI
17. Rosenblum JL, Castro VM, Moore CE, Kaplan LM (2012) Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults. Am J Clin Nutr 95(1):101–108 - DOI
18. Siddiqui SM, Chang E, Li J, Burlage C, Zou M, Buhman KK, Koser S, Donkin SS, Teegarden D (2008) Dietary intervention with vitamin D, calcium, and whey protein reduced fat mass and increased lean mass in rats. Nutr Res 28:783–790 - DOI
19. Sisley S, Arble DM, Chambers AP, Gutierrez-Aguilar R, He Y, Xu Y, Gardner D, Moore DD, Seeley RJ, Sandoval DA (2016) Hypothalamic vitamin D improves glucose homeostasis and reduces weight. Diabetes 65(9):2732–2741 - DOI
20. Foss YJ (2009) Vitamin D deficiency is the cause of common obesity. Med Hypothesis 72:314–322 - DOI
21. Zemel MB (2002) Regulation of adiposity and obesity risk by dietary calcium: mechanisms and implications. J Am Coll Nutr 21:146S-151S - DOI
22. Mirhosseini N, Vatanparast H, Mazidi M, Kimball SM (2018) Vitamin D supplementation, glycemic control, and insulin resistance in prediabetics: a meta-analysis. J Endocrinol Societ 2(7):687–709 - DOI
23. Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG (2003) Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J 17(3):509–511 - DOI
24. Hewison M (2010) Vitamin D and the immune system: new perspectives on an old theme. Endocrinol Metab Clin North Am 39:365–379 - DOI
25. Kolb H, Mandrup-Poulsen T (2005) An immune origin of type 2 diabetes? Diabetologia 48:1038–1050 - DOI
26. Borissova AM, Tankova T, Kirilov G, Dakovska L, Kovacheva R (2003) The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract 57:258–261 - PubMed
27. Fadda GZ, Akmal M, Lipson LG, Massry SG (1990) Direct effect of parathyroid hormone on insulin secretion from pancreatic islets. Am J Physiol 258:E975–E984 - PubMed
28. Amiri HL, Agah S, Mousavi SN, Hosseini AF, Shidfar F (2016) Regression of nonalcoholic fatty liver by vitamin D supplement: a double-blind randomized controlled clinical trial. Arch Iran Med 19(9):631–638
29. Corte CD, Carpino G, De Vito R, De Stefanis C, Alisi A, Cianfarani S, Overi D, Mosca A, Stronati L, Cucchiara S, Raponi M, Gaudio E, Byme CD, Nobili V (2016) Docosahexanoic acid plus vitamin D treatment improves features of NAFLD in children with serum vitamin D deficiency: results from a single centre trial. PLoS One 11(12): e0168216
30. Benedict M, Zhang X (2017) Non-alcoholic fatty liver disease: an expended review. World J Hepatol 9(16):715–732 - DOI
31. Geier A (2011) Shedding new light on vitamin D and fatty liver disease. J Hepatol 55:273–275 - DOI
32. Ding C, Wilding JP, Bing C (2013) 1,25-Dihydroxyvitamin D3 protects against macrophage-induced activation of NFκB and MAPK signalling and chemokine release in human adipocytes. PLoS One 8: e61707